T3N0M0 Prostate Cancer Staging
Prostate cancer T3N0M0 is locally advanced disease, classified as Stage III in the TNM staging system.
Staging Classification
T3N0M0 prostate cancer represents:
- T3: Tumor extends through the prostatic capsule (T3a = extracapsular extension; T3b = seminal vesicle invasion)
- N0: No regional lymph node involvement
- M0: No distant metastases
This corresponds to Stage III disease in the AJCC/TNM staging classification, indicating locally advanced prostate cancer that has breached the prostatic capsule but remains confined to the pelvic region without nodal or distant spread.
Clinical Significance and Prognosis
The evidence demonstrates that T3 disease, while locally advanced, still carries a favorable long-term prognosis with appropriate treatment:
Long-term survival data from retrospective series show over 60% cancer-specific survival at 15 years and over 75% overall survival at 10 years for men undergoing radical prostatectomy for T3 disease 1
For T3b-T4 disease specifically, cohort studies demonstrated 10-year cancer-specific survival exceeding 87% and overall survival of 65% 1
Patients treated with radiation therapy showed significantly better overall survival and disease-free survival outcomes 1
Treatment Implications
Stage III (T3N0M0) disease requires aggressive multimodal therapy rather than surgery or radiation alone. The contemporary standard involves:
- Definitive local therapy (radiation therapy or radical prostatectomy) combined with systemic treatment
- Radiation therapy is generally preferred over surgery for T3 disease based on superior outcomes 1
- Androgen deprivation therapy for 3 years is standard when combined with radiation 1
The key distinction is that T3N0M0 represents locally advanced but non-metastatic disease (Stage III), which differs fundamentally from N1 or M1 disease in terms of treatment approach and prognosis.